CEL-SCI (CVM) Reports 146 Patients Enrolled In Its Phase 3 Immunotherapy Head And Neck Cancer Trial
2/27/2014 9:55:57 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Approximately 146 patients have been enrolled in the Phase III study to date.
Help employers find you! Check out all the jobs and post your resume.
comments powered by